121 related articles for article (PubMed ID: 23261601)
1. Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides.
Secchi M; Longhi R; Vassena L; Sironi F; Grzesiek S; Lusso P; Vangelista L
Chem Biol; 2012 Dec; 19(12):1579-88. PubMed ID: 23261601
[TBL] [Abstract][Full Text] [Related]
2. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES.
Nardese V; Longhi R; Polo S; Sironi F; Arcelloni C; Paroni R; DeSantis C; Sarmientos P; Rizzi M; Bolognesi M; Pavone V; Lusso P
Nat Struct Biol; 2001 Jul; 8(7):611-5. PubMed ID: 11427892
[TBL] [Abstract][Full Text] [Related]
3. Critical role of the N-loop and beta1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity.
Vangelista L; Longhi R; Sironi F; Pavone V; Lusso P
Biochem Biophys Res Commun; 2006 Dec; 351(3):664-8. PubMed ID: 17083916
[TBL] [Abstract][Full Text] [Related]
4. Macrophages and lymphocytes differentially modulate the ability of RANTES to inhibit HIV-1 infection.
Gross E; Amella CA; Pompucci L; Franchin G; Sherry B; Schmidtmayerova H
J Leukoc Biol; 2003 Nov; 74(5):781-90. PubMed ID: 12960233
[TBL] [Abstract][Full Text] [Related]
5. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
6. Molecular engineering of RANTES peptide mimetics with potent anti-HIV-1 activity.
Lusso P; Vangelista L; Cimbro R; Secchi M; Sironi F; Longhi R; Faiella M; Maglio O; Pavone V
FASEB J; 2011 Apr; 25(4):1230-43. PubMed ID: 21199933
[TBL] [Abstract][Full Text] [Related]
7. Highly potent HIV inhibition: engineering a key anti-HIV structure from PSC-RANTES into MIP-1 beta/CCL4.
Gaertner H; Lebeau O; Borlat I; Cerini F; Dufour B; Kuenzi G; Melotti A; Fish RJ; Offord R; Springael JY; Parmentier M; Hartley O
Protein Eng Des Sel; 2008 Feb; 21(2):65-72. PubMed ID: 18178567
[TBL] [Abstract][Full Text] [Related]
8. Restricted variable residues in the C-terminal segment of HIV-1 V3 loop regulate the molecular anatomy of CCR5 utilization.
Hu Q; Napier KB; Trent JO; Wang Z; Taylor S; Griffin GE; Peiper SC; Shattock RJ
J Mol Biol; 2005 Jul; 350(4):699-712. PubMed ID: 15964018
[TBL] [Abstract][Full Text] [Related]
9. Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES.
Wilken J; Hoover D; Thompson DA; Barlow PN; McSparron H; Picard L; Wlodawer A; Lubkowski J; Kent SB
Chem Biol; 1999 Jan; 6(1):43-51. PubMed ID: 9889151
[TBL] [Abstract][Full Text] [Related]
10. Analyses of anti-HIV type 1 activity of a small CCR5 peptide antagonist.
Wang FY; He SY; Zhang ZJ; He LF; Chen XW; Teng T
AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1111-5. PubMed ID: 21375388
[TBL] [Abstract][Full Text] [Related]
11. Recognition of RANTES by extracellular parts of the CCR5 receptor.
Duma L; Häussinger D; Rogowski M; Lusso P; Grzesiek S
J Mol Biol; 2007 Jan; 365(4):1063-75. PubMed ID: 17101151
[TBL] [Abstract][Full Text] [Related]
12. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
13. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation.
Polo S; Nardese V; De Santis C; Arcelloni C; Paroni R; Sironi F; Verani A; Rizzi M; Bolognesi M; Lusso P
Eur J Immunol; 2000 Nov; 30(11):3190-8. PubMed ID: 11093134
[TBL] [Abstract][Full Text] [Related]
15. Soluble glycosaminoglycans Do not potentiate RANTES antiviral activity on the infection of primary macrophages by human immunodeficiency virus type 1.
Ylisastigui L; Bakri Y; Amzazi S; Gluckman JC; Benjouad A
Virology; 2000 Dec; 278(2):412-22. PubMed ID: 11118364
[TBL] [Abstract][Full Text] [Related]
16. Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers.
Vangelista L; Secchi M; Liu X; Bachi A; Jia L; Xu Q; Lusso P
Antimicrob Agents Chemother; 2010 Jul; 54(7):2994-3001. PubMed ID: 20479208
[TBL] [Abstract][Full Text] [Related]
17. Synthetic full-length and truncated RANTES inhibit HIV-1 infection of primary macrophages.
Ylisastigui L; Vizzavona J; Drakopoulou E; Paindavoine P; Calvo CF; Parmentier M; Gluckman JC; Vita C; Benjouad A
AIDS; 1998 Jun; 12(9):977-84. PubMed ID: 9662193
[TBL] [Abstract][Full Text] [Related]
18. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.
Hartley O; Gaertner H; Wilken J; Thompson D; Fish R; Ramos A; Pastore C; Dufour B; Cerini F; Melotti A; Heveker N; Picard L; Alizon M; Mosier D; Kent S; Offord R
Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16460-5. PubMed ID: 15545608
[TBL] [Abstract][Full Text] [Related]
19. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.
Jin J; Colin P; Staropoli I; Lima-Fernandes E; Ferret C; Demir A; Rogée S; Hartley O; Randriamampita C; Scott MG; Marullo S; Sauvonnet N; Arenzana-Seisdedos F; Lagane B; Brelot A
J Biol Chem; 2014 Jul; 289(27):19042-52. PubMed ID: 24855645
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of some peptides corresponding to the active region of RANTES for chemotaxis and evaluation of their anti-human immunodeficiency virus-1 activity.
Nishiyama Y; Murakami T; Kurita K; Yamamoto N
Chem Pharm Bull (Tokyo); 1997 Dec; 45(12):2125-8. PubMed ID: 9433785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
